Abbott Diabetes Care Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Abbott Diabetes Care Inc.
Tandem’s CSO Speaks On Insulin Pump Development And Its Challenges
Insulin pumps have lagged behind continuous glucose monitors in terms of market penetration due to their cost and the complex regulatory framework that surrounds them. Elizabeth Gasser, chief strategy officer at Tandem Diabetes spoke to Medtech Insight about these challenges and how the company is taking a slightly different approach to pumps.
Minute Insight: Abbott Teams Up With WeightWatchers In Diabetes Management
The companies will link Abbott’s blood glucose monitoring devices to WeightWatchers’ smartphone apps and weight loss program.
How Viable Is The Future Of The “Traditional” CGM?
Flagship products like Dexcom’s G7 and Abbott’s FreeStyle Libre 3 offer currently unrivalled accuracy of blood glucose measurement. However, as truly noninvasive technologies improve, the future basis for these companies’ growth is on shaky ground.
FDA Clears Abbott’s Libre 3
Abbott’s FreeStyle Libre 3 system will soon be available in the US. It is 70% smaller than the Libre 2 while also providing better accuracy.
- Monitoring Equipment & Devices
In Vitro Diagnostics
- Glucose Testing
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.